These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 17173053)

  • 1. The influence of cyclosporin alone, or cyclosporin and methotrexate, on the incidence of mixed haematopoietic chimaerism following allogeneic sibling bone marrow transplantation for severe aplastic anaemia.
    McCann S; Passweg J; Bacigalupo A; Locasciulli A; Locatelli F; Ryan J; Schrezenmeier H; Lawler M
    Bone Marrow Transplant; 2007 Jan; 39(2):109-14. PubMed ID: 17173053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA.
    Lawler M; McCann SR; Marsh JC; Ljungman P; Hows J; Vandenberghe E; O'Riordan J; Locasciulli A; Socié G; Kelly A; Schrezenmeier H; Marin P; Tichelli A; Passweg JR; Dickenson A; Ryan J; Bacigalupo A;
    Br J Haematol; 2009 Mar; 144(6):933-45. PubMed ID: 19183198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients.
    Kim HJ; Park CY; Park YH; Kim YJ; Kim DW; Min WS; Kim CC
    Bone Marrow Transplant; 2003 Jan; 31(2):79-86. PubMed ID: 12621487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial.
    Locatelli F; Bruno B; Zecca M; Van-Lint MT; McCann S; Arcese W; Dallorso S; Di Bartolomeo P; Fagioli F; Locasciulli A; Lawler M; Bacigalupo A
    Blood; 2000 Sep; 96(5):1690-7. PubMed ID: 10961865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis.
    Yagasaki H; Kojima S; Yabe H; Kato K; Kigasawa H; Sakamaki H; Tsuchida M; Kato S; Kawase T; Muramatsu H; Morishima Y; Kodera Y
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1603-8. PubMed ID: 19896085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation.
    Iravani M; Mousavi A; Gholibeikian S; Bahar B; Samiee S; Ashouri A; Eghbal L; Ghavamzadeh A
    Bone Marrow Transplant; 2005 Jun; 35(11):1095-9. PubMed ID: 15821773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants.
    Hoyt R; Ritchie DS; Roberts AW; Macgregor L; Curtis DJ; Szer J; Grigg AP
    Bone Marrow Transplant; 2008 Apr; 41(7):651-8. PubMed ID: 18176619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Favorable current prognosis after HLA-identical bone marrow transplantation for children with required severe aplastic anemia; evaluation of 30 years of bone marrow transplantation at the Leiden University Medical Center].
    van Steekelenburg M; van Weel-Sipman MH; Zwinderman AH; Hoogerbrugge PM; Vossen JM; Egeler RM
    Ned Tijdschr Geneeskd; 2002 Aug; 146(33):1542-6. PubMed ID: 12212502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CsA-based post-graft immunosuppression: the main factor for improving outcome of allografted patients with acquired aplastic anemia. A retrospective survey by the Spanish Group of Hematopoietic Transplantation.
    Arranz R; Conde E; Rodriguez-Salvanés F; Pajuelo FJ; Cabrera R; Sanz MA; Petit J; Bueno J; Maldonado J; Odriozola J; Conde JG; Brunet S; Carreras E; Iriondo A; Fernández-Rañada JM; Marín P;
    Bone Marrow Transplant; 2002 Feb; 29(3):205-11. PubMed ID: 11859392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful bone marrow transplantation in sensitized aplastic anemia patients using total lymphoid irradiation for conditioning: long-term follow-up.
    Zapatero A; Marín A; López M; Martín De Vidales C; Cerezo L; Domínguez P; Pérez Torrubia A
    Hematol Oncol; 1996 Dec; 14(4):165-72. PubMed ID: 9267462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up.
    Kahl C; Leisenring W; Deeg HJ; Chauncey TR; Flowers ME; Martin PJ; Sanders JE; Storb R
    Br J Haematol; 2005 Sep; 130(5):747-51. PubMed ID: 16115132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced-intensity conditioning regimens.
    Michallet AS; Fürst S; Le QH; Dubois V; Praire A; Nicolini F; Thomas X; Rafii H; Gebuhrer L; Michallet M
    Br J Haematol; 2005 Mar; 128(5):676-89. PubMed ID: 15725090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors.
    Hamblin M; Marsh JC; Lawler M; McCann SR; Wickham N; Dunlop L; Ball S; Davies EG; Hale G; Waldmann H; Gordon-Smith EC
    Bone Marrow Transplant; 1996 May; 17(5):819-24. PubMed ID: 8733704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y; Nagatoshi Y; Kawano Y; Okamura J
    Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic approach to molecular quantitative determination of mixed chimaerism following allogeneic bone marrow transplantation: an analysis of its applicability in a group of patients with severe aplastic anaemia.
    Hassan R; Bonamino MH; Braggio E; Lobo AM; Seuánez HN; Tabak DG; Zalcberg IR
    Eur J Haematol; 2004 Sep; 73(3):156-61. PubMed ID: 15287911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human leucocyte antigen-identical haematopoietic stem cell transplantation in major histocompatiblity complex class II immunodeficiency: reduced survival correlates with an increased incidence of acute graft-versus-host disease and pre-existing viral infections.
    Renella R; Picard C; Neven B; Ouachée-Chardin M; Casanova JL; Le Deist F; Cavazzana-Calvo M; Blanche S; Fischer A
    Br J Haematol; 2006 Sep; 134(5):510-6. PubMed ID: 16848795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia.
    George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
    Bone Marrow Transplant; 2007 Jul; 40(1):13-8. PubMed ID: 17450183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
    Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
    Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low mortality of children undergoing hematopoietic stem cell transplantation from 7 to 8/10 human leukocyte antigen allele-matched unrelated donors with the use of antithymocyte globulin.
    Sedlácek P; Formánková R; Keslová P; Srámková L; Hubácek P; Król L; Kulich M; Starý J
    Bone Marrow Transplant; 2006 Dec; 38(11):745-50. PubMed ID: 17041606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.